ICU: QUELIMMUNE sales surged, while adult-AKI trial enrollment shifted to mid-2027
SeaStar Medical (ICU) reported Q3 2026 revenue growth of 247% YoY, driven by QUELIMMUNE sales. Nine-month sales suggest FY2026 guidance of $2 million is achievable. NEUTRALIZE-AKI trial enrollment delayed to mid-2027, with adult-AKI PMA work ongoing.
How this was made

The 30-second read
Why it matters
The earnings beat and achievable guidance provide a fresh catalyst that could attract new buying interest, especially given the high growth rate.
Market read
The strong revenue growth and guidance update are likely to lift ICU's stock in the short term, with potential spill‑over to similar biotech peers.
What to watch
Potential regulatory hurdles for the adult‑AKI PMA and competition from other renal‑therapy candidates.
Background
SeaStar Medical Holding Corp (ICU) reported a 247% YoY increase in Q3 revenue and indicated FY2026 guidance of $2 M is within reach, while its NEUTRALIZE‑AKI trial timeline shifts to mid‑2027.
Ticker impact
Q3 revenue jumped 247% YoY and FY2026 guidance of $2 M is now within reach, indicating strong sales momentum.
likely upward pressure as investors price in stronger sales and achievable guidance
The disclosed revenue surge and attainable guidance are fresh, material facts that can move the stock.
Market effects
Boosts outlook for biotech firms with late‑stage AKI trials, may lift peer valuations.
Limited to US biotech sector; no broader regional effect.
Minor global impact, confined to specialty renal‑therapy market.
Counterpoint
If trial enrollment delays persist, the guidance may be overly optimistic, risking a pull‑back.
Key entities
- companySeaStar Medical Holding Corp
US‑listed biotech focused on acute kidney injury therapies.